MPO and chronic obstructive pulmonary disease: CHF6001 treatment decreased sputum inflammatory markers in COPD, including neutrophil chemoattractants CXCL8, LTB4, MMP9, and TNFα; however, no impact on sputum neutrophil count or markers of neutrophil activity (NE and MPO) was observed [107].